safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-300Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESСвязанный с альбуминовыми наночас тицами паклитаксел – первые шаги нанотехнологий в клиническую практикуNanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practiceАляутдинР. Н.AlyautdinR. N.РомановБ. К.RomanovB. K.ЛепахинВ. К.ЛепахинВ. К.БунятянН. Д.BunyatyanN. D.МеркуловВ. А.MerkulovV. A.МироновА. Н.MironovA. N.Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации, МоскваРоссияScientific Centre for Expert Evaluation of Medicinal Products Russian FederationRussian Federation201401062022021016Copyright © Аляутдин Р.Н., Романов Б.К., Лепахин В.К., Бунятян Н.Д., Меркулов В.А., Миронов А.Н., 20222022Аляутдин Р.Н., Романов Б.К., Лепахин В.К., Бунятян Н.Д., Меркулов В.А., Миронов А.Н.Alyautdin R.N., Romanov B.K., Лепахин В.К., Bunyatyan N.D., Merkulov V.A., Mironov A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/300

Паклитаксел является эффективным противоопухолевымсредством, используемым для лечения рака молочной железы, легких, желудка и поджелудочной железы. Однако, его побочные эффекты и использование токсичного Кремофора EL в качестве растворителя ограничивают спектр применения этого препарата. Связанный с альбуминовыми наночастицами паклитаксел (САН-паклитаксел) целенаправленно транспортируется в опухолевые ткани, что увеличивает его противоопухолевый эффект и снижает выраженность побочного действия.

Paclitaxel is an effective antitumor agent used for treatment of breast cancer, lung, stomach and pancreas. However, its own adverse effects and the use of toxic Cremophor EL as the solvent limit the application range of this drug. Associated with the albumin-bound nanoparticle paclitaxel (paclitaxel SAN) specifically transported into tumor tissue. This leads to an increase in the antitumor effect, and it reduces the severity of side effects.

нанотехнологииальбуминовые наночастицыпаклитакселnanotechnologyalbumin nanparticlespaclitaxelReferencesBawa R. Patents and n anomedicine.// Nanomedicine 2007; 2: 351–374.Bawa R. Patents and n anomedicine.// Nanomedicine 2007; 2: 351–374.Kreuter J, Speiser PP. New adjuvants on a polymethylmethacrylate base.//Infect Immun. 1976 Jan;13(1):204-10.Kreuter J, Speiser PP. New adjuvants on a polymethylmethacrylate base.//Infect Immun. 1976 Jan;13(1):204-10.Nishida N, Hirohisa Yano H, Nishida T, et al. Angiogenesis in cancer. //Health Risk Man ag 2006; 2(3): 213–219.Nishida N, Hirohisa Yano H, Nishida T, et al. Angiogenesis in cancer. //Health Risk Man ag 2006; 2(3): 213–219.Bern acki J., Dobrowolska D., Nierwiñska et al. Physiology and pharmacological role of the blood-brain barrier// Pharmacological Reports. 2008. Vol.- 60. P. 600–622.Bern acki J., Dobrowolska D., Nierwiñska et al. Physiology and pharmacological role of the blood-brain barrier// Pharmacological Reports. 2008. Vol.- 60. P. 600–622.Sabeque A.J., Wandel C., He H. Increased drug delivery to the brain by P-glycoprotein inhibitors// Clin. Pharmacol. Ther. 2000.- Vol. 68.- P. 231- 237.Sabeque A.J., Wandel C., He H. Increased drug delivery to the brain by P-glycoprotein inhibitors// Clin. Pharmacol. Ther. 2000.- Vol. 68.- P. 231- 237.Rogalska A, Szwed M, Rychlik B. The connection between the toxicity of anthracyclines and their ability to modulate the P-glycoprotein-mediated transport in A549, HepG2, and MCF-7 cells. Scientific World Journ al. 2014. V. 19. Р. 819548.Rogalska A, Szwed M, Rychlik B. The connection between the toxicity of anthracyclines and their ability to modulate the P-glycoprotein-mediated transport in A549, HepG2, and MCF-7 cells. Scientific World Journ al. 2014. V. 19. Р. 819548.Alyautdin, R., Khalin, I., Nafeeza,M. I.et al. Nanoscale Drug Delivery Systems and the Blood_Brain Barrier.// Int. J. Nanomed. 2014.V. 9. P. 795–811.Alyautdin, R., Khalin, I., Nafeeza,M. I.et al. Nanoscale Drug Delivery Systems and the Blood_Brain Barrier.// Int. J. Nanomed. 2014.V. 9. P. 795–811.Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis..// Adv Drug Deliv Rev. 2002. V.54(5) .P.631–51.Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis..// Adv Drug Deliv Rev. 2002. V.54(5) .P.631–51.Шаменков Д.А., Петров В.Е., Аляутдин Р.Н. Влияние аполипопротеинов на транспорт даларгина через гематоэнцефалический барьер. //Бюлл. экспер. биол. и мед. 2006. №12. С. 659-662.Шаменков Д.А., Петров В.Е., Аляутдин Р.Н. Влияние аполипопротеинов на транспорт даларгина через гематоэнцефалический барьер. //Бюлл. экспер. биол. и мед. 2006. №12. С. 659-662.Miele E., Spinelli G., Ermanno Miele. Albumin-bound formulation of paclitaxel (Abraxane®ABI-007) in the treatment of breast cancer.// Int. J. of Nanomed. 2009. V.4. P.99–105.Miele E., Spinelli G., Ermanno Miele. Albumin-bound formulation of paclitaxel (Abraxane®ABI-007) in the treatment of breast cancer.// Int. J. of Nanomed. 2009. V.4. P.99–105.Rowinsky EK, Donehower RC. Paclitaxel (Taxol).// N Engl J Med.1995. V.332. P.1004–1014.Rowinsky EK, Donehower RC. Paclitaxel (Taxol).// N Engl J Med.1995. V.332. P.1004–1014.Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol.// J. Clin. Oncol. 1990. V.8. P.1263–1268.Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol.// J. Clin. Oncol. 1990. V.8. P.1263–1268.Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodyn amic relationshi ps in humans. //J. Clin. Oncol. 1995. V.13. P.180–190.Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodyn amic relationshi ps in humans. //J. Clin. Oncol. 1995. V.13. P.180–190.Kloover JS, den Bakker MA, Gelderblom H, et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens. Br. J. Cancer. //2004. V.90. P. 304–305.Kloover JS, den Bakker MA, Gelderblom H, et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens. Br. J. Cancer. //2004. V.90. P. 304–305.ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin. Pharmacokinet. 2003. V.42. P.665–685.ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin. Pharmacokinet. 2003. V.42. P.665–685.Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel n anoparticle formulation of paclitaxel in patients with advanced nonhematologic malign ancies. J. Clin. Oncol. //2005. V.23(31). P.7785–7793.Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel n anoparticle formulation of paclitaxel in patients with advanced nonhematologic malign ancies. J. Clin. Oncol. //2005. V.23(31). P.7785–7793.Hawkins MJ, Soon-Shiong P, Desai N. Protein n anoparticles as drug carriers in clinical medicine.//Adv. Drug Deliv. Rev. 2008.V. 60. P.876–885.Hawkins MJ, Soon-Shiong P, Desai N. Protein n anoparticles as drug carriers in clinical medicine.//Adv. Drug Deliv. Rev. 2008.V. 60. P.876–885.Desai N, Trieu V, Yao Z, et al.: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin- bound paclitaxel,Desai N, Trieu V, Yao Z, et al.: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin- bound paclitaxel,ABI- 007, compared with cremophor-based paclitaxel. //Clin. Cancer Res. 2012. V. 14. P. 1317–1324. 16ABI- 007, compared with cremophor-based paclitaxel. //Clin. Cancer Res. 2012. V. 14. P. 1317–1324. 16Xia C.Q., Smith P. Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation.//. Mol. Pharmacol. 2012. V. 82. P. 1008–1021.Xia C.Q., Smith P. Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation.//. Mol. Pharmacol. 2012. V. 82. P. 1008–1021.Salah-Eddin Al-Batran a Michael Geisslerb Thomas Seufferleinc et al/ Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms Action.// Oncol. Re.s Treat. 2014V. 37. P.128–134.Salah-Eddin Al-Batran a Michael Geisslerb Thomas Seufferleinc et al/ Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms Action.// Oncol. Re.s Treat. 2014V. 37. P.128–134.Gardner ER, Dahut WL, Scri pture CD, et al.: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and n ab-paclitaxel.// Clin Cancer Res. 2008.V14. P.4200–4205.Gardner ER, Dahut WL, Scri pture CD, et al.: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and n ab-paclitaxel.// Clin Cancer Res. 2008.V14. P.4200–4205.Ibrahim NK, Desai N, Legha S, et al.: Phase I and pharmacokinetic study of ABI-007, a Cremophorfree, protein-stabilized, n anoparticle formulation of paclitaxel.// Clin. CancerIbrahim NK, Desai N, Legha S, et al.: Phase I and pharmacokinetic study of ABI-007, a Cremophorfree, protein-stabilized, n anoparticle formulation of paclitaxel.// Clin. CancerRes. 2002. V.8. P. 1038–1044.Res. 2002. V.8. P. 1038–1044.Socinski MA, Bondarenko I, Karaseva N. Weekly n ab-paclitaxel in combin ation with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patientsSocinski MA, Bondarenko I, Karaseva N. Weekly n ab-paclitaxel in combin ation with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patientswith advanced non-small-cell lung cancer: fin al results of a phase III trial//. J. Clin. Oncol. 2012. V.30. P.2055-2062.with advanced non-small-cell lung cancer: fin al results of a phase III trial//. J. Clin. Oncol. 2012. V.30. P.2055-2062.

The authors declare that there are no conflicts of interest present.